BARD1 and neuroblastoma: Four pathogenic or likely pathogenic germline BARD1 variants (those which are capable or likely capable of disrupting function/causing disease, denoted in red) were found in patients diagnosed with pediatric cancers including neuroblastoma, glioma, and B-cell acute lymphoblastic leukemia.